The risk of developing rare blood clots is higher for people who get COVID-19 than for those who are vaccinated, according to a study published Thursday by Oxford University.
The likelihood of suffering from cerebral venous sinus thrombosis – the condition that led federal health officials to discontinue Johnson & Johnson this week – is up to 10 times higher after being infected with coronavirus than after received a blow, according to the study.
“[Findings] they should be taken into account when considering the balance between the risks and benefits of vaccination, “Paul Harrison, head of the Oxford Translational Neurobiology Group, told a news conference on Thursday.
During the study, which was used to develop the AstraZeneca vaccine in Europe, the researchers looked at the number of coagulation cases in the two weeks after the diagnosis of COVID-19.
They also looked at how many people suffered from the condition two weeks after receiving a single dose of Pfizer, Moderna and AstraZeneca vaccines.
The researchers found that the risk of developing the condition was 10 times higher after taking COVID-19 than after receiving Pfizer or Moderna vaccines and eight times higher after receiving AstraZeneca.
The study did not include data on the Johnson & Johnson vaccine, which was discontinued Tuesday by federal health officials after six women reported suffering from a clotting condition, including a 45-year-old man who died.
Like the Johnson & Johnson vaccine in the United States, the AstraZeneca cage has caught fire due to possible links to brain blood clotting in Europe.
Denmark has stopped using AstraZeneca after an investigation “showed real and serious side effects”, according to health officials. Other countries have limited the use of the vaccine to older age groups, who appear to be less affected by clots.